Developing Heparan Sulfate Glycan Array

项目名称：硫酸乙酰肝素聚糖芯片的研制 本研究的目的是建立一种高通量的方法来研究乙酰肝素与蛋白质之间的相互作用。 硫酸盐（HS）和蛋白质。HS是一种高度硫酸化的多糖，具有广泛的生物活性， 功能协调发展的Glycan Therapeutics是一家专业从事HS相关研究产品的公司。在这一建议中， HS阵列技术将使用微量滴定板格式和微阵列格式构建。的 该公司的优势在于能够使用 化学酶法，允许以克级合成HS寡糖。这种合成能力 将确保以低成本获得寡糖底物，并使聚糖治疗剂具有充分的 控制底物的纯度。这种独特的优势将使聚糖治疗产生高 高质量的HS微量滴定板和HS微阵列芯片，价格合理。目的1是为了制备HS 基于HS阵列的微量滴定板。HS微量滴定板的主要优点是可重复使用， 方便.除酶标仪外，无需其他设备。此外，该方法可以 扩展到研究HS在基于细胞的功能测定中的作用。目的二是制备HS基因芯片 法该技术将允许使用多核苷酸筛选非常大量的HS寡糖和蛋白质。 非常少量的碳水化合物和蛋白质样本。HS微阵列技术将很容易 与现有的碳水化合物阵列方法集成在一个专门研究碳水化合物的中心设施中， 筛选 在I期研究中，将60种HS寡糖的文库固定在微量滴定板或微阵列上 用于生物筛选载玻片。将对HS微量滴定板或阵列载玻片进行彻底检测，以确保 质量.在II期研究中，微量滴定板和阵列载玻片上的寡糖数量将 扩展到200个，以充分代表与自然源分离的HS结构。成功将导致 方便和可靠的方法，以改善糖科学的研究。

Project title: Developing heparan sulfate glycan array This proposal is aimed at developing a high throughput method to study the interactions between heparan sulfate (HS) and proteins. HS is a highly sulfated polysaccharide displaying a wide range of biological functions. Glycan Therapeutics is a company specialized in HS related research products. In this proposal, an HS array technique will be constructed using both a microtiter plate format and a microarray format. The strength of the company is the capability of synthesizing structurally defined HS oligosaccharides using the chemoenzymatic method, allowing the synthesis of HS oligosaccharide in gram scale. This synthetic capability will ensure access to the oligosaccharide substrates at low cost and allows Glycan Therapeutics to have full control over the purity of the substrates. This unique strength will enable Glycan Therapeutics to produce high quality HS microtiter plates and HS micro-array chips at an affordable price. Aim 1 is designed to prepare HS microtiter plates based HS array. The major advantage of HS microtiter plate is that they are reusable and convenient. No additional equipment other than a microplate reader is needed. Furthermore, this method can be expanded to investigate the roles of HS in cell-based functional assays. Aim 2 is to prepare HS microarray technique. This technique will allow screening a very large number of HS oligosaccharides and proteins using very small amounts of carbohydrate and protein samples. The HS microarray technology will be readily integrated with existing carbohydrate-array methods in a centralized facility specialized in carbohydrate screening. In phase I studies, a library of 60 HS oligosaccharides will be affixed on a microtiter plate or on a microarray slide for biological screening. The HS microtiter plates or array slides will be tested thoroughly to ensure quality. In the phase II studies, the number of oligosaccharides on the microtiter plates and array slides will be expanded to 200 to fully represent the structures of HS isolated from natural sources. Success will lead to a convenient and reliable approach for improving research in glycosciences.